Details of the Drug

General Information of Drug (ID: DM31VZT)

Drug Name
CAD-106
Synonyms
Amilomotide; Alzheimers disease vaccine, Cytos/Novartis; Immunodrug vaccines (Alzheimers disease), Cytos/Novartis; Beta amyloid 1-6 peptide/Qbeta virus-like particle conjugate (Alzheimer's disease), Cytos/Novartis
Indication
Disease Entry ICD 11 Status REF
Alzheimer disease 8A20 Phase 2/3 [1]
Drug Type
Vaccine
Cross-matching ID
TTD ID
D0I3VT

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Amyloid beta A4 protein (APP) TTE4KHA A4_HUMAN Not Available [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Alzheimer disease
ICD Disease Classification 8A20
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Amyloid beta A4 protein (APP) DTT APP 1.60E-02 -0.07 -0.31
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 ClinicalTrials.gov (NCT02565511) A Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease.
2 The second-generation active Abeta immunotherapy CAD106 reduces amyloid accumulation in APP transgenic mice while minimizing potential side effects. J Neurosci. 2011 Jun 22;31(25):9323-31.